Login to Your Account



Shire Paying Jerini $519M for HAE Compound Firazyr

By Nuala Moran


Monday, July 7, 2008
LONDON - Shire Ltd. is buying Jerini AG in a cash deal valuing the German company at €328 million (US$519 million) to acquire Firazyr, (Icatibant) a treatment for hereditary angioedema (HAE), which is due to be launched in Europe by the end of the year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription